Granules set up a new state-of-the-art Research Centre in 10,000 square feet area at ALEAP Industrial Area, Pragathi Nagar, Hyderabad.

This milestone effort has helped us to make a successful entry into an enhanced product portfolio. The Research & Development (R&D) Centre and the Kilo-Lab focus on full scale generic API development. They also supplement the existing R&D efforts in our lab in Pune, which currently focuses on sustainable technology development.

At the Granules Research Center, innovation is the result of the R&D efforts at API and Finished Dosage spaces. We invest into R&D to develop products that create intellectual wealth and commercialize cost-effective, quality products in diversified therapeutic areas.

Our scientists always look for anything and everything ‘non-obvious’. The R&D department, with over 50 scientists, currently aims to work on products that strengthen our competitive position in the market, primarily focusing on differentiated portfolio. Formulation R&D efforts, at Granules, are directed towards vertical integration with our own APIs and filings, done by ourselves and our partners.

The Granules Research Centre is focused on revitalizing our growth engine to balance short-, mid- and long-term scientific and business goals. It is committed to offering superior and affordable solutions for products with intrinsic challenges at the chemistry and engineering areas, while creating its own intellectual property. The emphasis is on developing differentiated technologies, which play a key role in import substitution.

Our team aspires to focus on different classes of projects; some of which can generate revenue in the short-term, while others in the future. The pipeline is being designed to cater to products of variable complexities in the areas of chemistry, IP, regulatory, engineering and manufacturing. The center’s infrastructure has been and is being developed, while prioritizing attention on safety and quality.